FH.NE Filament Health (NEO) at C$0.01 on 11 Feb 2026: Oversold bounce setup

FH.NE stock trades at C$0.01 on 11 Feb 2026 after a sharp intraday slip, marking a -33.33% move and heavy intraday interest of 929,483 shares. Filament Health Corp. (FH.NE) on the NEO exchange operates in Canadian healthcare research and extraction of natural psychedelics. The price sits well below the 50-day and 200-day averages, creating a classic oversold bounce candidate for short-term traders looking for a defined risk entry. Meyka AI’s real-time signals identify the setup, but liquidity, negative earnings and small market cap demand strict risk control.

FH.NE stock price snapshot and intraday action

Filament Health Corp. (FH.NE) opened at C$0.01, hit a day low of C$0.005 and a day high of C$0.015, with last trade at C$0.01. The market cap is C$3,926,910.00 and shares outstanding are 392,691,000, reflecting a microcap structure and volatile intraday swings. Average volume is 4,885,995 shares, so today’s 929,483 shares equals a moderate liquidity pick-up versus the stock’s long-term flow.

Technical setup: oversold bounce signals for FH.NE stock

Price is materially below the 50-day (C$0.02) and 200-day (C$0.03) averages, signalling deep short-term weakness that can drive mean-reversion attempts. Volatility measures show ATR C$0.01, and Keltner center at C$0.01, implying tight intraday ranges where small orders move price materially. For an oversold bounce trade consider a staged entry between C$0.005 and C$0.01, a stop under C$0.005, and initial targets at C$0.02 and C$0.05 for a measured risk-reward.

Fundamentals and valuation for Filament Health Corp. (FH.NE stock)

The company reports EPS -0.02 and a negative PE (displayed -0.50), with price-to-sales near 12.57 and price-to-book around 1.50, signalling a high revenue multiple against scant revenues. Cash per share is about C$0.001 and the current ratio is 0.44, underlining short-term liquidity pressure. These fundamentals support a speculative classification and argue for micro-sized position sizing if trading the oversold bounce.

Meyka AI grade and forecast for FH.NE stock

Meyka AI rates FH.NE with a score out of 100: 61.89 / 100 | Grade B | Suggestion: HOLD. This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month median C$0.02 target, implying roughly +100.00% versus the current C$0.01 price; forecasts are model-based projections and not guarantees.

Risks, catalysts and a practical oversold-bounce trading plan

Key risk drivers are low liquidity, small market cap, negative margins and weak short-term balance-sheet ratios that can amplify downside. Near-term catalyst is the next earnings date listed for 2025-03-31, and any trial or IP news could spark rallies. Tactical plan: limit size to a small portfolio weight, use limit-entry and hard stops, book partial gains at C$0.02, and tighten stops if volume dries up.

Sector context and comparative metrics for FH.NE stock

Filament sits in Healthcare, Drug Manufacturers – Specialty & Generic, a sector that has lagged with one‑year weakness and elevated volatility. Compared with sector averages, FH.NE shows weaker liquidity and negative profitability metrics while price-to-book is near sector norms. This context makes FH.NE a high-risk, event-driven play rather than a fundamentals-led buy for longer-term healthcare investors.

Final Thoughts

Short-term traders looking at FH.NE stock can view today’s drop to C$0.01 as a disciplined oversold-bounce setup with clearly defined entries, stops and targets. Meyka AI’s model projects a C$0.02 12-month median target, representing an implied +100.00% upside from the current price, but the company’s weak liquidity, negative EPS (-0.02) and low current ratio (0.44) raise the probability of further downside. Practical trade rules: limit exposure to a small portfolio slice, enter between C$0.005–C$0.01, place a stop below C$0.005, and scale out at C$0.02 and C$0.05. These levels reflect intraday structure, average price bands and Meyka AI’s risk-adjusted scenario analysis. Forecasts are model-based projections and not guarantees; treat FH.NE as speculative and use strict risk management.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.